Pharmacogenomics and Big Data in medical oncology: developments and challenges
Files
Date
2024
Authors
Marcu, L.G.
Marcu, D.C.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Therapeutic Advances in Medical Oncology, 2024; 16:1-18
Statement of Responsibility
Conference Name
Abstract
Medical oncology, through conventional chemotherapy as well as targeted drugs, remains an important component of cancer patient management, particularly for systemic disease. Despite advances in all areas of medical oncology, certain challenges persist in the form of drug resistance and severe normal tissue toxicity. These unwanted effects can be counteracted through a patient-tailored treatment approach, which in chemotherapy is translated as pharmacogenomics. This research field investigates the way genetic makeup influences a patient’s response to various drugs with the aim to minimize trial-and-error associated with drug administration. The paper introduces the role, advances and challenges of pharmacogenomics, highlighting the importance of Big Data mining to reveal the mechanisms behind drug–gene pair interaction for better patient outcomes. International consortiums have prioritized their focus on the clinical implementation of pharmacogenomics while tackling the challenges ahead: data standardization, ethical aspects and the education of physicians and patients alike to comprehend the power of pharmacogenomics to transform medical oncology.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2024 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 License, which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage) (https://creativecommons.org/licenses/by/4.0/.)